Abstract
Alzheimer’s disease (AD) is associated with cognitive and functional impairment as well as neuropsychiatric sequelae, including psychotic symptoms such as delusions and hallucinations. Strong evidence supports the need to study delusions separate from hallucinations. Integrating the epidemiology, clinical correlates, and neuropathological and genetic literature for delusions in AD allows us to speculate on etiology and mechanisms. Plaque and tangle deposition in individuals with susceptible alleles of serotonergic, muscarinic, nicotinic, or Apoε4 genes appears to result in disruption of cortical circuitry, culminating in delusions. While delusions in AD correspond to a phenotype distinct from AD without delusions, subtypes of delusions may also define further distinct clinical entities. Persecutory delusions may occur earlier in the illness and have a more significant genetic component than misidentification delusions, which are associated with increased cognitive impairment and advanced dementia. Clearly distinguishing between these two syndromes is essential to making progress in the area of delusions in AD.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170–7.
Wiener PK, Kiosses DN, Klimstra S, et al. A short-term inpatient program for agitated demented nursing home residents. Int J Geriatr Psychiatry. 2001;16:866–72.
Alzheimer A. Uber eine eigenartige rkrankung der hirnrinde. Allg Z Psychiat Psych Gerichtl Med. 1907;64:146–8.
Fischer C, Bozanovic-Sosic R, Norris M. Review of delusions in dementia. Am J Alzheimer’s Dis Other Dements. 2004;19:19–23.
Holt AE, Albert ML. Cognitive neuroscience of delusions in aging. Neuropsychiatr Dis Treat. 2006;2:181–9.
Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29–34.
Schneider LS, Katz IR, Park S, et al. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003;11:414–25.
Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16:1037–42.
Mizrahi R, Starkstein SE, Jorge R, et al. Phenomenology and clinical correlates of delusions in Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:573–81.
Cook SE, Miyahara S, Bacanu SA, et al. Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatry. 2003;11:406–13.
Perez-Madrinan G, Cook SE, Saxton JA, et al. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am J Geriatr Psychiatry. 2004;12:449–56.
Forstl H, Besthorn C, Burns A, et al. Delusional misidentification in Alzheimer’s disease: a summary of clinical and biological aspects. Psychopathology. 1994;27:194–9.
Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022–30.
Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer’s disease to the subsequent emergence of psychosis. Int psychogeriatrics IPA. 2009;21:78–85.
Ostling S, Gustafson D, Blennow K, et al: Psychotic Symptoms in a Population- Based Sample of 85-Year-Old Individuals With Dementia. J Geriatr Psychiatry Neurol.
Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int psychogeriatrics IPA. 2010;22:346–72.
Sweet RA, Bennett DA, Graff-Radford NR, et al. Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain. 2010;133:1155–62.
Harciarek M, Kertesz A. The prevalence of misidentification syndromes in neurodegenerative diseases. Alzheimer disease and associated disorders 2008; 22:163–169
• Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194:212–9. This was a large longitudinal study that assessed the prevalence and incidence of NPS in dementia. Importantly, misidentifications were assessed separately from persecutory delusions and had differing incidence rates as well as differing associations in factor analysis.
Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer’s disease with and without delusions. Am J Psychiatry. 1992;149:184–9.
Hamilton L, Fay S, Rockwood K. Misplacing objects in mild to moderate Alzheimer’s disease: a descriptive analysis from the VISTA clinical trial. J Neurol Neurosurg Psychiatry. 2009;80:960–5.
Murayama N, Iseki E, Endo T, et al. Risk factors for delusion of theft in patients with Alzheimer’s disease showing mild dementia in Japan. Aging Ment Health. 2009;13:563–8.
•• Nagata T, Ishii K, Ito T, et al. Correlation between a reduction in Frontal Assessment Battery scores and delusional thoughts in patients with Alzheimer's disease. Psychiatry Clin Neurosci. 2009;63:449–54. This was a very important study of the role of cognition and delusions in AD. Methodologically, this study is important because it assessed persecutory delusions as separate from misidentifications and used the FAB rather than a crude global measure such as the MMSE.
Nedjam Z, Devouche E, Dalla Barba G. Confabulation, but not executive dysfunction discriminate AD from frontotemporal dementia. Eur J Neurol. 2004;11:728–33.
Fischer CE, Verhoeff NP, Churchill K, et al. Functional outcome in delusional Alzheimer disease patients. A systematic review. Dement Geriatr Cogn Disord. 2009;27:105–10.
Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.
Forstl H, Burns A, Levy R, et al. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer’s disease. Br J Psychiatry. 1994;165:53–9.
Mukaetova-Ladinska EB, Harrington CR, Roth M, et al. Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer’s disease. In: Bergener M, Finkel SI, editors. Treating Alzheimer’s and other dementias. New York: Springer; 1995. p. 57–80.
Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57:1165–73.
Lai MK, Lai OF, Keene J, et al. Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57:805–11.
Sweet RA, Panchalingam K, Pettegrew JW, et al. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002;23:547–53.
Shinno H, Inagaki T, Miyaoka T, et al. A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer’s disease. J Neurol Sci. 2007;260:132–8.
Tunstall N, Owen MJ, Williams J, et al. Familial influence on variation in age of onset and behavioural phenotype in Alzheimer’s disease. Br J Psychiatry. 2000;176:156–9.
Avramopoulos D, Fallin MD, Bassett SS. Linkage to chromosome 14q in Alzheimer’s disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet. 2005;132:9–13.
DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer’s disease: a review. J Alzheimers Dis. 2010;19:761–80.
Weiner MF, Vega G, Risser RC, et al. Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer’s disease. Biol Psychiatry. 1999;45:633–8.
Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer’s disease. Neurology. 2002;58:1182–8.
Chang JB, Wang PN, Chen WT, et al. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology. 2004;63:1105–7.
Spalletta G, Bernardini S, Bellincampi L, et al. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer’s disease with late onset. Eur J Neurol. 2006;13:176–82.
van der Flier WM, Staekenborg S, Pijnenburg YA, et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord. 2007;23:42–6.
Pritchard AL, Harris J, Pritchard CW, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:123–6.
Assal F, Alarcon M, Solomon EC, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249–53.
Angelucci F, Bernardini S, Gravina P, et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102 T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal study. J Alzheimers Dis. 2009;17:203–11.
Lam LC, Tang NL, Ma SL, et al. 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:523–6.
Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer’s disease. Hum Mol Genet. 1998;7:1507–9.
Borroni B, Grassi M, Agosti C, et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging. 2006;27:1595–603.
Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777–9.
Craig D, Hart DJ, McCool K, et al. The interleukin 1beta gene promoter polymorphism (−511) acts as a risk factor for psychosis in Alzheimer’s dementia. Ann Neurol. 2004;56:121–4.
• Carson R, Craig D, Hart D, et al. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer’s disease. Neuromolecular Med. 2008;10:377–84. This was a newer genetic study showing an association of a novel gene in the study of delusions in dementia, but one that has been studied in schizophrenia, demonstrating a potential association between the two.
Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942–52.
Acknowledgments
Dr. Mulsant has served on boards for the Center for Addiction and Mental Health (CAMH) and the CAMH Foundation and has received grant support from the National Institutes of Health and the Canadian Institutes of Health Research.
Dr. Mamo has received grant support from the National Institute of Mental Health and the Canadian Institute of Health Research.
Disclosure
Dr. Mulsant has received donations of medication for use in National Institutes of Health–funded clinical trials from Bristol-Myers Squibb, Pfizer, and Wyeth and previously held stock in AkzoNobel, Alkermes, AstraZeneca, Biogen Idec, Celsion Corp., Elan Corp., Eli Lilly and Company, Forest Laboratories, Orchestra Therapeutics, and Pfizer.
Dr. Mamo has received grant support from Pfizer.
Drs. Ismail, Fischer, and Schweizer, and Minh-Quan Nguyen reported no potential conflicts of interest relevant to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ismail, Z., Nguyen, MQ., Fischer, C.E. et al. Neurobiology of Delusions in Alzheimer’s Disease. Curr Psychiatry Rep 13, 211–218 (2011). https://doi.org/10.1007/s11920-011-0195-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-011-0195-1